## HIMS: Hims & Hers Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.5% below STRENGTH zone (4.0-10.0%); PEG 1.95 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($30.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. (HIMS) Risk Channels and Responsive Allocation**
- Source: Stock Traders Daily | 20251221T000855 | Somewhat-Bearish | Relevance: 100%
- This article provides a stock analysis for Hims & Hers Health Inc. Class A (NASDAQ: HIMS), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The analysis reports elevated downside risk due to a lack of additional long-term support signals.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $48 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.39M) |
| Sells | 21 ($2.56M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 67.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.2% (+1198.1%)
- Blackrock Inc.: 11.5% (+1.6%)
- Vanguard Group Inc: 8.9% (+4.5%)
- Capital World Invest: 8.6% (+1.2%)
- Farallon Capital Man: 4.9% (+30.8%)

### Key Risks

1. High beta (2.41) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. High short interest (36.6%, 2.6 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 24.0% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.95 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 26%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.9B |
| Beta | 2.41 |
| 52W Range | $23.97 - $72.98 |
| Short Interest | 36.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.95 |
| Forward P/E | 52.9 |
| Current P/E | 72.9 |
| YoY Growth | 37.8% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from -4.5% to -7.5% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.5pp (needs >4.0% for momentum thesis). AM_20 at -6.6% indicates price below own 20MA trend. Underperforming sector by 7.2pp, stock-specific weakness. Below SMA200 (0.76x), long-term trend not supportive. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.54% (CS: 4) | Weak |
| RSI_14 | 38.6 | Neutral |
| MACD Histogram | 0.00 | Bearish |
| vs SMA20 | 0.934x | Below |
| vs SMA50 | 0.841x | Below |
| vs SMA200 | 0.760x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $34.80
- **Stop Loss:** $30.62 (12.0% risk)
- **Target:** $38.98 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 287
- **Position Value:** $9,987.60
- **Portfolio %:** 9.99%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-23 (Est: $0.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.10 | $0.06 | -41.0% |
| 2025Q2 | $0.16 | $0.17 | +3.2% |
| 2025Q1 | $0.12 | $0.20 | +65.0% |
| 2024Q4 | $0.11 | $0.11 | +0.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*